's Heeren Loo

At 's Heeren Loo researchers are evaluating how therapeutic drug monitoring can reduce side‑effects of antipsychotics such as risperidone and aripiprazole in children and adolescents diagnosed with autism spectrum disorder. The aim is to improve treatment safety and effectiveness.

• Therapeutic drug monitoring for antipsychotics
• Weight gain assessment in pediatric patients
• Pharmacokinetic safety studies
• Optimizing dosing strategies

This work supports personalized medication approaches and seeks to enhance quality of life for young patients facing mental health challenges.

The site conducts investigations into the impact of medications such as pipamperone and aripiprazole on behaviors that challenge among individuals with intellectual disability. The purpose is to determine whether these agents can provide safer behavioral control compared with periods without antipsychotic treatment.

• Effectiveness of pipamperone in reducing challenging behaviors
• Comparative analysis with aripiprazole
• Behavioral outcomes in intellectual disability
• Non‑pharmacological behavior management insights

Findings aim to guide clinicians toward evidence‑based choices for managing difficult behaviors while minimizing unnecessary medication exposure.

In addition to medication studies, researchers at the centre explore broader mental health aspects linked to autism spectrum disorder, focusing on strategies to prevent adverse effects and support overall well‑being. The objective is to refine therapeutic techniques that address both core symptoms and associated mental health concerns.

• Comorbidity management in autism
• Side‑effect mitigation strategies
• Improving adolescent mental health outcomes
• Integrating diagnostic tools with treatment plans

Located in Amersfoort, Netherlands, the Medical Service at 's Heeren Loo collaborates with a single dedicated investigator to advance these research priorities.